Reunion Biotech Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$10.1M
- Investors
-
9
Reunion Biotech General Information
Description
Developer of medical hydrogel products intended to provide new medical solutions. The company provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolism and innovative anti-tumor drugs, enabling clients with self-developed ready-to-use PEG hydrogel materials.
Contact Information
Website
www.reunionbiotech.comCorporate Office
- Room 221, 2nd Floor, Building 5
- Number 1180 Xingxian Road, Jiading District
- Shanghai, 201821
- China
Corporate Office
- Room 221, 2nd Floor, Building 5
- Number 1180 Xingxian Road, Jiading District
- Shanghai, 201821
- China
Reunion Biotech Timeline
Reunion Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 28-Feb-2026 | $10.1M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series B) | 19-Jan-2024 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A1) | 23-Sep-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 23-Dec-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 15-Jul-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 12-Jan-2021 | $1.53M | $1.53M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 17-Dec-2018 | Completed | Startup |
Reunion Biotech Patents
Reunion Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026137930-A1 | Pelvic organ group module for ct-guidable puncture injection via posterior fornix of vagina | Pending | 27-Dec-2024 | ||
| US-20260355389-A1 | Double-network soft tissue filling medical hydrogel, preparation method therefor, and use thereof | Pending | 29-Dec-2023 | ||
| WO-2025139024-A1 | Double-network soft tissue filling medical hydrogel, preparation method therefor, and use thereof | Inactive | 29-Dec-2023 | ||
| WO-2025055386-A1 | Two-component in-situ-curing heat-insulating hydrogel containing gas microspheres, and preparation method therefor | Inactive | 12-Sep-2023 | ||
| US-20250129218-A1 | Hydrogel kit capable of being quickly dissolved as required and use method thereof | Pending | 22-Aug-2023 | C08J3/075 |
Reunion Biotech Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dingxin Capital | Venture Capital | Minority | ||
| Qingdao Conson Financial Holdings | Venture Capital | Minority | ||
| Jiaxing Deshi Private Equity Fund Management | Growth/Expansion | Minority | ||
| Qiming Venture Partners | Venture Capital | Minority | ||
| Proxima Capital | Venture Capital | Minority |
Reunion Biotech FAQs
-
When was Reunion Biotech founded?
Reunion Biotech was founded in 2018.
-
Where is Reunion Biotech headquartered?
Reunion Biotech is headquartered in Shanghai, China.
-
What industry is Reunion Biotech in?
Reunion Biotech’s primary industry is Therapeutic Devices.
-
Is Reunion Biotech a private or public company?
Reunion Biotech is a Private company.
-
What is Reunion Biotech’s current revenue?
The current revenue for Reunion Biotech is .
-
How much funding has Reunion Biotech raised over time?
Reunion Biotech has raised $31M.
-
Who are Reunion Biotech’s investors?
Dingxin Capital, Qingdao Conson Financial Holdings, Jiaxing Deshi Private Equity Fund Management, Qiming Venture Partners, and Proxima Capital are 5 of 9 investors who have invested in Reunion Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process